mRNA疫苗接种在预防COVID-19相关有创机械通气与死亡中的效果——美国,2021年3月至2022年1月
采用病例对照设计,评估2021年3月11日至2022年1月24日期间在21家美国医疗中心住院的≥18岁成人中mRNA疫苗对有创机械通气(IMV)或院内死亡的保护效果。在1,440例接受IMV或死亡的COVID-19病例中,307例(21%)在发病前接种2或3剂;在6,104例对照中,4,020例(66%)接种2或3剂。疫苗对IMV或院内死亡的总有效性为90%(95%CI=88%-91%),2剂为88%(95%CI=86%-90%),3剂为94%(95%CI=91%-96%),奥密克戎优势期3剂为94%(95%CI=88%-97%)。
要点
- mRNA疫苗对COVID-19相关IMV或院内死亡总有效性90%(95%CI=88%-91%)。
- 2剂有效性88%(95%CI=86%-90%),3剂94%(95%CI=91%-96%)。
- 奥密克戎优势期3剂有效性94%(95%CI=88%-97%)。
核心结论
- COVID-19 mRNA疫苗在预防COVID-19相关死亡和需IMV治疗的呼吸衰竭方面高度有效。
- CDC推荐所有符合接种条件者接种疫苗并保持COVID-19疫苗接种最新状态。
研究设计与样本
- 采用病例对照设计,评估mRNA疫苗对COVID-19相关IMV和院内死亡的有效性。
- 研究对象为2021年3月11日至2022年1月24日期间在21家美国医疗中心住院的≥18岁成人。
- 比较前瞻性入组的COVID-19病例患者(接受IMV或住院28天内死亡)与无COVID-19的住院对照患者的既往接种情况(发病前2或3剂 vs 0剂)。
- 期间主要流行变异株为B.1.1.7(Alpha)、B.1.617.2(Delta)和B.1.1.529(Omicron)。
主要发现
- 1,440例接受IMV或死亡的COVID-19病例中,307例(21%)在发病前接种2或3剂。
- 6,104例对照中,4,020例(66%)接种2或3剂。
- 1,440例接受IMV或死亡的病例中,接种者较未接种者年龄更大(中位年龄69岁 vs 55岁)、免疫抑制比例更高(40% vs 10%),慢性病更多(两者p<0.001)。
- 疫苗对IMV或院内死亡的总有效性为90%(95%CI=88%-91%),2剂为88%(95%CI=86%-90%),3剂为94%(95%CI=91%-96%)。
- 奥密克戎优势期3剂有效性为94%(95%CI=88%-97%)。
临床怎么用
- CDC推荐所有符合接种条件者接种疫苗并保持COVID-19疫苗接种最新状态。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
COVID-19 mRNA vaccines (BNT162b2 [Pfizer-BioNTech] and mRNA-1273 [Moderna]) are effective at preventing COVID-19-associated hospitalization (1-3). However, how well mRNA vaccines protect against the most severe outcomes of these hospitalizations, including invasive mechanical ventilation (IMV) or death is uncertain. Using a case-control design, mRNA vaccine effectiveness (VE) against COVID-19-associated IMV and in-hospital death was evaluated among adults aged ≥18 years hospitalized at 21 U.S. medical centers during March 11, 2021-January 24, 2022. During this period, the most commonly circulating variants of SARS-CoV-2, the virus that causes COVID-19, were B.1.1.7 (Alpha), B.1.617.2 (Delta), and B.1.1.529 (Omicron). Previous vaccination (2 or 3 versus 0 vaccine doses before illness onset) in prospectively enrolled COVID-19 case-patients who received IMV or died within 28 days of hospitalization was compared with that among hospitalized control patients without COVID-19. Among 1,440 COVID-19 case-patients who received IMV or died, 307 (21%) had received 2 or 3 vaccine doses before illness onset. Among 6,104 control-patients, 4,020 (66%) had received 2 or 3 vaccine doses. Among the 1,440 case-patients who received IMV or died, those who were vaccinated were older (median age = 69 years), more likely to be immunocompromised* (40%), and had more chronic medical conditions compared with unvaccinated case-patients (median age = 55 years; immunocompromised = 10%; p<0.001 for both). VE against IMV or in-hospital death was 90% (95% CI = 88%-91%) overall, including 88% (95% CI = 86%-90%) for 2 doses and 94% (95% CI = 91%-96%) for 3 doses, and 94% (95% CI = 88%-97%) for 3 doses during the Omicron-predominant period. COVID-19 mRNA vaccines are highly effective in preventing COVID-19-associated death and respiratory failure treated with IMV. CDC recommends that all persons eligible for vaccination get vaccinated and stay up to date with COVID-19 vaccination (4).
引用
- Tenforde MW, Self WH, Gaglani M, et al. Effectiveness of mRNA Vaccination in Preventing COVID-19-Associated Invasive Mechanical Ventilation and Death - United States, March 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022. PMID: 35324878. doi:10.15585/mmwr.mm7112e1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。